Is Thymosin Alpha-1 Legal in Kentucky?

HealthRX.com

No US approval, and Kentucky status is not confirmed here

Print or save as PDF

Key numbers

  • 1.6 mgDose of the finished Zadaxin injection sold outside the United StatesSource: fda.gov, as cited Nov 8, 2026
  • 4 yes to 17 noFDA advisory committee vote against adding the peptide to the compounding bulks listSource: fda.gov, as cited Nov 8, 2026
  • category 3FDA outsourcing facility category for the peptide, nominated without adequate supportSource: fda.gov, as cited Nov 8, 2026
  • category 2Former FDA safety category for the peptide, left after nominators withdrewSource: fda.gov, as cited Nov 8, 2026
  • FDA approval / None; no US application exists [1]
  • Approved elsewhere / Italy, India and Hong Kong, per FDA [1]
  • FDA interim categories, state-licensed pharmacies / In none of the three; the category 1 policy does not apply [2]
  • FDA pharmacy bulks list / FDA proposed not adding it; advisory committee voted 4 yes, 17 no [3]
  • FDA outsourcing facility list / Category 3, 'nominated without adequate support' [5]
  • HHS peptide draft policy / Not one of the six peptides covered [6]

Is it approved in the United States?

No. Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide, and a Drugs@FDA search found no US application for it [1]. It holds four US orphan drug designations, but orphan designation is a separate process and is not an approval [1].

It is approved as a medicine in some other countries. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the United States and is not interchangeable with bulk peptide powder [1]. No US-approved dose exists [1].

Can a Kentucky pharmacy compound it from bulk powder?

Federal rules let a state-licensed pharmacy use a bulk substance only if a USP or NF monograph exists for it, if it is a component of an FDA-approved drug, or if it appears on FDA's list of bulk substances that may be used in compounding [7]. Thymosin alpha-1 is not FDA-approved and is in none of FDA's three interim categories for state-licensed pharmacies, so FDA's category 1 policy does not cover it [1][2][7].

FDA has also proposed that thymosin alpha-1 not be added to the compounding bulks list. On December 4, 2024 its Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [3]. The peptide is also not one of the six in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) [6].

For outsourcing facilities, FDA places thymosin alpha-1 in category 3, meaning it was nominated without adequate support [5].

What FDA's safety findings say

FDA lists thymosin alpha-1 in its 'nominated but withdrawn' table; it had been in category 2 (significant safety risks) and came off because the nominators withdrew [8]. FDA's stated concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [8].

What this means in Kentucky

The Kentucky Board of Pharmacy regulates pharmacy practice in the Commonwealth [4]. FDA's lists above are federal, and none of the material here names a Kentucky statute, regulation or board action on thymosin alpha-1, so a Kentucky-specific permission or restriction is not confirmed on this page. The federal position stands on its own: there is no FDA-approved thymosin alpha-1 product [1].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Is thymosin alpha-1 FDA-approved in the United States, according to the article?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is thymosin alpha-1 legal in Kentucky?
No US-approved thymosin alpha-1 product exists, and FDA's category 1 policy for pharmacy compounding does not apply to it [1][2]. A Kentucky-specific permission or restriction naming it is not confirmed here.
Can a Kentucky compounding pharmacy make thymosin alpha-1?
FDA does not place thymosin alpha-1 in any of the three interim categories for state-licensed pharmacies, so its category 1 policy does not apply. Whether a Kentucky pharmacy could compound it cannot be determined from those lists alone [2][7].
Is thymosin alpha-1 approved in other countries?
Yes, in some. FDA lists Italy, where Zadaxin is an adjuvant to influenza vaccination in immunocompromised people, India for chronic hepatitis B in adults with compensated liver disease, and Hong Kong [1]. The European Medicines Agency holds only an orphan designation, not an approval [1].
Why did the FDA advisory committee vote against thymosin alpha-1?
On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [3].
Is thymosin alpha-1 part of the October 2026 HHS peptide policy?
No. That draft enforcement-discretion policy covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, not thymosin alpha-1 [6].
Show all 8 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Kentucky?